Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2004 3
2005 3
2006 6
2007 7
2008 7
2009 7
2010 5
2011 6
2012 7
2013 17
2014 11
2015 10
2016 9
2017 10
2018 16
2019 7
2020 18
2021 24
2022 34
2023 12
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29856900

196 results

Results by year

Filters applied: . Clear all
Page 1
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, Iwadou S, Horiguchi S, Takahashi H, Suzuki E, Moriguchi M, Tsuji K, Otsuka T, Asagi A, Kojima Y, Takada R, Morizane C, Mizuno N, Ikeda M, Ueno M, Furuse J. Kobayashi S, et al. Cancer Sci. 2018 Aug;109(8):2549-2557. doi: 10.1111/cas.13656. Epub 2018 Jun 27. Cancer Sci. 2018. PMID: 29856900 Free PMC article.
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
Chae H, Cho H, Yoo C, Kim KP, Jeong JH, Chang HM, Kang J, Lee HC, Lim YS, Kim KM, Shim JH, Lee SS, Park DH, Song TJ, Hwang S, Song GW, Moon DB, Lee YJ, Lee JH, Ryoo BY. Chae H, et al. Int J Biol Markers. 2018 Nov;33(4):432-438. doi: 10.1177/1724600818777239. Epub 2018 Jun 6. Int J Biol Markers. 2018. PMID: 29874985 Free article.
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Konstantinidis IT, Groot Koerkamp B, Do RK, Gönen M, Fong Y, Allen PJ, D'Angelica MI, Kingham TP, DeMatteo RP, Klimstra DS, Kemeny NE, Jarnagin WR. Konstantinidis IT, et al. Cancer. 2016 Mar 1;122(5):758-65. doi: 10.1002/cncr.29824. Epub 2015 Dec 22. Cancer. 2016. PMID: 26695839 Free PMC article.
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Kudo M, et al. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7. Lancet Gastroenterol Hepatol. 2018. PMID: 29631810 Clinical Trial.
196 results